The U.S. Food and Drug Administration (FDA) announced on Friday, after market close, that it is investigating the death of an 8-year-old boy who had received Elevidys, Sarepta Therapeutics Inc.’s (NASDAQ:SRPT) gene therapy for Duchenne muscular dystrophy.
The death occurred on June 7, 2025, prompting the FDA to request and receive a voluntary suspension of product distribution to investigate the safety concerns.
